Evaluation of the effect of memantine on diabetic neuralgia(diabetic nouropathy)(DN)

The study of efficacy of memantin on nouropathy in diabetic patients-double blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180404039187N5

Enrollment

100

Registered

2019-09-05

Start date

2019-05-15

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nouropathy. Type 2 diabetes mellitus with diabetic polyneuropathy

Interventions

Intervention 1: Intervention group: received memantine 5 mg twice daily in the first week and received memantine 10 mg from week 2 to week 8 twice daily. Intervention 2: Control group: routin care wh

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with diabetic neuropathy (PDN) aged between 18 and 75 years who have been diagnosed with PDN due to physical examinations. And patients treated with gababirzin (gabapentin and pregabalin)

Exclusion criteria

Exclusion criteria: Pregnancy- Lactation- Cardiovascular disease- The presence of other neuropathies, such as neuropathy caused by herpes and trigeminal neuralgia, and ...- Sensitization to memantine or other formulation components- Uncontrolled hypertention- Epilepcy- Liver failure- Renal insufficiency with creatinine clearance less than 30 ml / min

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar level. Timepoint: At the beginning and 3 months after intervention. Method of measurement: Enzymatic method with Pars Azmoon kit.;Glycosylated hemoglobin (three months sugar)(A1C). Timepoint: At the beginning and 3 months after intervention. Method of measurement: Immunoturbidimetry? autoanalyzers assay.;Heat and cold test. Timepoint: At the beginning and 3 months later. Method of measurement: Using a thermophile tool (Diagnostic Tool for Neuropathy).;Diapazon test. Timepoint: At the beginning and 3 months later. Method of measurement: Using Diapazone (Diagnostic Tool for Neuropathy).;Monofilament. Timepoint: At the beginning and 3 months later. Method of measurement: Using a monofilament device (a diagnostic tool for neuropathy).;Pain and numbness on the soles of the feet and hands. Timepoint: At the beginning and 3 months later. Method of measurement: DN4 questionnaire.	—

Measure

Time frame

Fasting blood sugar level. Timepoint: At the beginning and 3 months after intervention. Method of measurement: Enzymatic method with Pars Azmoon kit.;Glycosylated hemoglobin (three months sugar)(A1C). Timepoint: At the beginning and 3 months after intervention. Method of measurement: Immunoturbidimetry? autoanalyzers assay.;Heat and cold test. Timepoint: At the beginning and 3 months later. Method of measurement: Using a thermophile tool (Diagnostic Tool for Neuropathy).;Diapazon test. Timepoint: At the beginning and 3 months later. Method of measurement: Using Diapazone (Diagnostic Tool for Neuropathy).;Monofilament. Timepoint: At the beginning and 3 months later. Method of measurement: Using a monofilament device (a diagnostic tool for neuropathy).;Pain and numbness on the soles of the feet and hands. Timepoint: At the beginning and 3 months later. Method of measurement: DN4 questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElnaz Shaseb

Tabriz University of Medical Sciences

Elnaz_shaseb_64@yahoo.com+98 144933344198

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026